Kintara Therapeutics (NASDAQ:KTRA) released its quarterly earnings results on Tuesday. The company reported ($0.13) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.16) by $0.03, Fidelity Earnings reports.
NASDAQ:KTRA opened at $0.82 on Thursday. Kintara Therapeutics has a 12-month low of $0.80 and a 12-month high of $3.35. The firm has a market capitalization of $26.61 million, a P/E ratio of -0.38 and a beta of 1.53. The stock’s fifty day simple moving average is $1.43 and its 200-day simple moving average is $1.58.
KTRA has been the subject of a number of recent analyst reports. Maxim Group reaffirmed a “buy” rating and set a $6.00 price target on shares of Kintara Therapeutics in a report on Friday, July 2nd. HC Wainwright assumed coverage on Kintara Therapeutics in a research report on Tuesday. They issued a “buy” rating and a $6.00 price objective on the stock.
Kintara Therapeutics, Inc is a clinical and biopharmaceutical company, which focuses on the development and commercialization of new cancer therapies. Its pipeline includes the VAL-083 and REM-001. The company was founded by Jeffrey A. Bacha, Dennis M. Brown, and William J. Garner on June 24, 2009 and is headquartered in San Diego, CA.
Further Reading: Moving Average (MA)
Receive News & Ratings for Kintara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kintara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.